Novartis to Buy Mariana Oncology for Up to $1.75 Billion in Boost to Radioligand Therapy Business
By Mauro Orru
Novartis agreed to acquire U.S. biotechnology company Mariana Oncology for up to $1.75 billion, in a deal that bolsters its radioligand therapy pipeline and efforts to develop cancer treatments.
The Swiss pharmaceutical company said Thursday that it would pay $1 billion up front for Watertown, Mass.-based Mariana Oncology, with an additional $750 million in payments upon completion of certain milestones.
Mariana Oncology focuses on novel radioligand therapies, or RLTs, to treat cancers. RLTs bind to specific receptors on the surface of certain types of tumors. Once bound, emissions from therapeutic radioisotopes cause DNA damage that can inhibit cell growth and replication.
Novartis currently has two approved RLTs for patients with metastatic castration-resistant prostate cancer and certain types of gastroenteropancreatic neuroendocrine tumors.
The deal is subject to customary closing conditions.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
May 02, 2024 07:36 ET (11:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
GE Aerospace Stock Has Skyrocketed 86%. Is It a Buy?
-
2 Undervalued Dividend Stocks the Best Managers Are Buying
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates